Title

Presentation

Beyond Air, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.14.

Operator: Good afternoon, and welcome, everyone, to the Beyond Air Financial Results Call for the Fiscal Quarter and Year Ended March 31, 2025. [Operator Instructions] And now I would like to turn the call over to Corey Davis with LifeSci Advisors. Please go ahead.

Corey George Davis: Thank you, operator. Good afternoon, everyone, and thank you for joining us. Today, after the market closed, we issued a press release announcing the operational highlights and financial results for Beyond Air’s fourth quarter of fiscal year 2025 ended March 31, 2025. A copy of this press release can be found on our website, beyondair.net, under the News & Events section. Before we begin, I’d like to remind everyone that we will be making comments and various remarks about future expectations, plans and prospects, which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

We encourage everyone to review the company’s filings with the SEC, including, without limitation, the company’s most recent Form 10-K and Form 10-Q which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, June 17, 2025. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I’ll turn the call over to Steve Lisi, Chairman and Chief Executive Officer of Beyond Air.

Go ahead, Steve.

Steven Adam Lisi: Thanks, Corey, and good afternoon to everyone. With me here today is Doug Larson, our Chief Financial Officer. We are quite pleased with the progress we’ve made over the past year. For the fiscal year ended March 31, 2025, we reported a 220% increase in revenue to $3.7 million compared with $1.2 million for the same period last year. All of this growth came from U.S. sales, the majority coming from hospitals signed during the back half of the year. As a result, we have tremendous revenue growth built in to kick off fiscal year 2026, along with several new growth drivers as I will discuss in a moment. With this in mind, we have decided to also announce that we are on track to report revenue of at least $1.7 million for the quarter ending in just 2 weeks on June 30, 2025, which translates to greater than a 45% sequential quarterly growth and greater than 145% year-over-year growth.

In addition, we are providing revenue guidance of $12 million to $16 million for the full fiscal year ending March 31, 2026. This level of projected growth moving forward shows how we are overcoming the barriers to entry in the nitric oxide market and are well on our way to making LungFit PH the market leader. The more customers use LungFit PH, the more confidence grows in the product and our ability to provide top-tier service. This is an exciting time for our team and our shareholders. Let me now dig a little deeper into the numbers for the fiscal fourth quarter of 2025 and growth drivers for fiscal 2026. The commercial team’s efforts have led to a steady flow of new hospital contracts throughout fiscal year 2025. During the fourth quarter, we saw 3 new hospital starts and 3 hospitals renew their contracts.

As I’ve mentioned recently, we have established a solid customer base across key target regions in the U.S. We are pleased and thankful that many of these customers have made themselves available as references for LungFit PH over recent months, which has proven to be a valuable tool when establishing new accounts. Further to the customer reference approach, we have partnered with Vanderbilt University Medical Center, naming them as the first luminary site for LungFit PH. Through this program, we will work alongside the Vanderbilt team to further optimize LungFit products and explore new opportunities to enhance hospital-based nitric oxide therapy. In addition, Vanderbilt has made themselves available to better showcase the full utility of LungFit PH technology to respiratory therapists, anesthesiologists, nurses, and other relevant clinicians at hospitals considering adopting our cylinder-free nitric oxide delivery system.

This collaboration marks a major milestone in our core mission to redefine tankless nitric oxide delivery and drive continued innovation in respiratory care. Now I would like to update you on the status of LungFit PH II, our next-generation system. As announced yesterday, we have submitted a PMA supplement to FDA. LungFit PH II is smaller, lighter and designed for air and ground transportation while still delivering all the revolutionary features of the current FDA-approved system. Additional improvements include a more intuitive user interface, more functional backup system, adjustable alarm volume and significantly less frequent maintenance. All of these improvements were made with extensive input from our customers. We anticipate that the anticipated FDA approval of the second- generation system and subsequent introduction to the U.S. market will have a major impact on our market share, total NO volume and logistics within the hospital.

Looking outside the U.S. Over the course of just the past 6 months, we have quickly ramped up our commercial program across Europe, Southeast Asia and the Middle East. These activities have included securing key regulatory approvals, including CE Mark, as well as signing distribution agreements across more than 2 dozen countries covering over 2 billion lives. Today, we announced that the team has recently signed several new international distribution partnerships for the following countries: India, Italy, Latvia, Lithuania, Estonia, Ukraine, Kuwait, Kazakhstan, Israel, and Poland. As a reminder, because the LungFit system generates NO from room air unlike other systems that require NO-filled cylinders, we are opening an enormous new opportunity in geographical areas around the world where hospitals are unable to obtain nitric oxide supply or do not use nitric oxide due to the logistical difficulties associated with cumbersome cylinder-based systems.

I am pleased to report that we have already shipped more than a dozen units of LungFit PH to customers outside the U.S. over the course of just the past few weeks. As a result, we plan to see a meaningful contribution from these activities reflected in our financial results starting in the back half of fiscal 2026 and beyond. Turning to Beyond Cancer. As previously reported, they received regulatory approval in Israel to begin a Phase Ib trial for low- volume UNO or ultra-high concentration nitric oxide in combination with anti-PD-1 therapy in late-stage cancer patients who have failed anti-PD-1 therapy. This remains an area of high unmet patient need. Timing for the initiation of this study is under review. On to NeuroNOS, our subsidiary focused on therapies for autism special disorders.

We are pleased to announce recently that the U.S. FDA granted Orphan Drug Designation to our lead investigational therapy, BA-102, which is being developed for the treatment of Phelan-McDermid syndrome, a syndrome associated with autism spectrum disorder. As many of you are aware, this designation provides key development incentives, including 7 years of market exclusivity upon approval, tax credits for qualified clinical trials, waiver of FDA application fees and access to FDA protocol assistance. NeuroNOS will meet with FDA later this year to get an idea of the path to human studies, which we expect to begin late in calendar 2026. The excitement around our autism program goes beyond our walls. This is evident by our ability to recruit leaders in the field to our Scientific Advisory Board.

Just recently, we announced the appointment of Nobel Prize laureate, Professor Dan Shechtman to the NeuroNOS SAB. We believe bringing in Professor Shechtman to join Professor Roger Kornberg from Stanford University on this Board brings unparalleled scientific expertise to the NeuroNOS team. During the March quarter, NeuroNOS published a peer-reviewed journal article in Translational Psychiatry, which presented breakthrough research by its Chief Scientific Officer, Professor Haitham Amal, which shows compelling evidence of a novel mechanism in the early stages of Alzheimer’s disease. These new preclinical data further underscore the consistency and power of NeuroNOS’ platform and offers new hope for the development of effective therapies for this devastating condition.

Building on the excitement around the data and progress of its programs, NeuroNOS announced at the end of March that it completed a $2 million equity financing from private investors as part of a larger funding round. This investment will accelerate the preclinical development of NeuroNOS’ small molecule drug designed as an injectable or oral treatment for children with autism. Turning to the corporate side. We’re excited to announce today the appointment of Bob Goodman to our Board of Directors effective June 13, 2025. Bob is a seasoned health care executive and Board Director, who brings decades of commercial leadership experience from across the medical technology, pharmaceutical services and medical device industries. His career has included executive roles at BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher and Pfizer.

Our Board and management team look forward to working with Bob as we continue to build positive momentum across the commercial side of our business. Before I conclude my comments today, I want to mention that our LungFit GO program is still moving along. We are dedicated to bringing this therapy to market to improve the lives of patients suffering with lung infections. We plan to meet with FDA prior to year-end to discuss the clinical path forward. We continue to make significant progress in executing against the strategies for each of our businesses. Past year showed just a glimpse of how LungFit PH will transform the global NO landscape for the better and gives us a solid foundation from which to continue to build. Beyond Air team will continue to be diligent on its path to profitability and improving the lives of patients in need of the benefits of nitric oxide.

Now I will turn it over to our CFO, Doug Larson.

Douglas Quinton Larson: Thanks, Steve, and good afternoon, everyone. Our financial results for the fourth quarter fiscal year 2025, which ended March 31, 2025, are as follows: revenue for the fiscal year ended March 31, 2025, increased 220% to $3.7 million compared with $1.2 million for the fiscal year ended March 31, 2024. We’re showing $1.7 million loss in gross profit for the fiscal year 2025 compared to $1.3 million for fiscal year 2024. Cost of revenue of $5.4 million were recognized in the fiscal year compared to $2.5 million in the fiscal year ended March 31, 2024. Cost of revenue exceeded revenue, primarily driven by the depreciation of LungFit devices and onetime upgrade costs to systems. Research and development expenses were $16.9 million for fiscal year 2025 compared with $24.4 million for fiscal year ended March 31, 2024.

The decrease of $7.5 million was primarily attributed to a decrease in salaries, stock-based compensation and, to a lesser extent, from clinical and preclinical study expenses. SG&A expenses for the year ended March 31, 2025 and March 31, 2024, were $26 million and $37.3 million, respectively. The decrease of $11.3 million was attributed primarily to a reduction in salaries and stock-based compensation costs. Other expense was $3.9 million compared to $1.3 million a year ago. The increase in other expense of $2.6 million was mainly due to a noncash loss recorded upon the retirement of Avenue Capital debt. Net loss attributed to common stockholders of Beyond Air, Inc. was $46.6 million or a loss of $0.69 per share, basic and diluted. Our net loss for the fiscal year ended March 31, 2024, was $60.2 million or a loss of $1.82 per share, basic and diluted.

Net cash burn for the year was $44.1 million, which is more than 28% lower than previous year. We’ve talked in previous quarters how we’ve been laser focused on fixed cost reduction, in R&D and in our supply chain. Now that we’re wrapping up spend on development of our next-generation LungFit device, we’ll see further reduction in our cash burn in Q1 and again in Q2. I would like to take a moment and expand a bit on our cost reduction efforts. Over the past 6 quarters, we’ve reduced operating expenses from north of $17 million to just above $7 million in the current quarter. This translates to a 58% reduction. We believe the trough in our operating expenses will either be in the coming June quarter or the September quarter. Please do not interpret that expenses will be moving up significantly in the December quarter.

Expenses will move up in proportion to our commercial performance to maintain our excellence in service and take advantage of coming opportunities. As of March 31, 2025, the company had cash, cash equivalents and marketable securities of $6.9 million. Please note this does not include the $1 million payment we received from Getz Healthcare nor the additional $2 million investment into our existing synthetic royalty debt structure, both of which we received after March 31, 2025. We believe our cash, cash equivalents, marketable securities and existing financing vehicles will be sufficient to allow us to support our current operating plans well into calendar 2026 and potentially to profitability, provided we continue to hit our internal revenue estimates and control costs at Beyond Air.

And with that, I’ll hand the call back to Steve.

Steven Adam Lisi: Thanks, Doug. We’ll now take some questions. Operator?

Operator: [Operator Instructions] Our first question is from Marie Thibault with BTIG.

Marie Yoko Thibault: Congrats on the progress here. Wanted to ask my first question here about LungFit 2.0 (sic) [ LungFit PH II ] Great to see that get in. Wanted to understand if that system approval is being assumed in the fiscal year ’26 guide — guidance range that you’ve given us, and how we should think about the selling dynamics ahead of that potential approval. Is that something where hospitals see that coming approval and say, “Hey, I want to get exposure to LungFit before that comes out?” Is it they wait a little bit as they’re waiting for that next-gen system? Help us think about some of those dynamics.

Steven Adam Lisi: Thanks, Marie. Fiscal ’26 guidance does not include the second-generation system at all. And to answer your other question, we don’t promote the Gen 2, obviously, until we get approval. So people know it exists, obviously, and they do inquire. But I think it’s — the focus is on Gen 1. That’s what we’re promoting now and that’s what we’re marketing and pushing. And yes, I mean, obviously, there are some hospitals that are interested in getting exposure to Gen 1 immediately. And then there are others who will choose to wait. So we’ve seen both at this point.

Marie Yoko Thibault: Okay. Very encouraging. Very helpful, Steve. Wanted to ask also about OUS. You’ve gotten several shipments out there, it sounds like, of units. What are we understanding about what some of those contracts look like? Is there any difference in how hospitals use this versus how they use it within U.S. hospitals? Any trends or specific countries we should be looking toward or any other catalysts OUS? Just want to get a little closer to that market.

Steven Adam Lisi: Yes. I think it’s a little early for us to see any trends in actual hospitals outside the U.S. Right now, our shipments are initial shipments to distributors, and they’re taking those and using them for demonstration to get interest to have hospital placements. And there’s much more of a tender process outside the United States than in the U.S., so it takes a little bit longer to get into the hospitals. So I think the back half of this fiscal year, we’ll see a big upswing on the international side as we get hospital placements and we’ll get some trends at that point. But our initial work in the market outside the U.S. is showing consistency in terms of how they use nitric oxide. Outside the U.S., cardiac surgery is on label so they’re definitely using it in that area. But again, it’s similar to how it’s used in the United States.

Marie Yoko Thibault: Okay. Very helpful update.

Operator: Our next question is from Jason Wittes with ROTH Capital.

Jason Hart Wittes: Congrats on the progress here. On the PMA submission, do you have an expected time line for when we may see an approval for that for — for LungFit PH II?

Steven Adam Lisi: Jason, did you ask me when FDA is going to approve it?

Jason Hart Wittes: I just — do you have an estimate is what I’m asking. And I guess I’d add to that, how should we think about a potential launch? I think you had indicated earlier that it’s kind of a staged launch versus an immediate bolus type hit. I’m just curious about the dynamics around what we might expect when the FDA approves this device.

Steven Adam Lisi: Okay. So yes, I’m going to stay away from the exact timing on an FDA approval. I mean, everybody kind of knows what’s going on at FDA right now. There’s a little bit of an upheaval. So let’s just kind of let things settle in. It will take a few months for us to interact with FDA and get a better understanding of their questions on our application. And perhaps I can give some more on time lines or better guidance on timing at that moment in time. But as for the launch for Gen 2, obviously, we’re going to prep for that as we work with FDA. There’s always a period where you need to build up inventory and you need to scale up your manufacturing. So it will take a couple of months and then we will try to keep up with demand. That will probably be the challenge that we have post approval.

Jason Hart Wittes: Okay. That’s a totally appropriate answer, I get it. And then appreciate the guidance, which looks quite strong. We’re at the low end. There’s a big range there. I mean, what has to happen to get to the higher end of that range for the $12 million to $16 million that you’re kind of hinting or pointing to for 2026?

Steven Adam Lisi: Yes. It’s not really that big of a range. I mean, a $4 million range. I guess it seems that way because it’s a small $12 million to $16 million, it’s not 100 to 104…

Jason Hart Wittes: Percentage-wise, certainly, but dollars, right, go ahead.

Steven Adam Lisi: But I mean, you can get a couple of contracts that are a good size, and it can move you a few million dollars. We can get some approvals — regulatory approvals overseas for some big countries and get some big orders in. So it’s not — to us, it’s not that big of a range because things can swing dramatically with some of the things that we have going on in the pipeline. So that’s kind of how we view it. We look at it as we feel pretty comfortable getting to the low end of that. There are a couple of things in the works that could get us into the mid and upper range of that. And if anything changes, we’ll update you. I mean, I know the next call we have is in early August so there might not be any kind of change at that point.

But certainly, by November, we’ll have a good idea of how we’re looking for getting into the range or perhaps maybe we get lucky. Maybe it will be at the high end or higher. We just don’t know at this point. There’s too many moving parts and it’s only June. So it’s exciting for us.

Jason Hart Wittes: Got it. That’s helpful. And then maybe just another clarification on — did I hear correctly so basically on the expense line, there’ll be further reductions until — expected through September and then you basically grow with revenues on the expense line? Is that the right way to think about modeling the P&L?

Steven Adam Lisi: Yes, exactly.

Jason Hart Wittes: Okay. Congrats on the PMA submission.

Operator: Our next question is from Justin Walsh with JonesTrading.

Justin Howard Walsh: Now you guys are supplying globally, I was wondering, I guess, the degree to which you’re seeing impacts or worried about impacts from some of the emerging geopolitical questions. I mean, we have a moving target with U.S. tariffs, and you mentioned that you’re supplying to Ukraine and, of course, you have ties in Israel. So just curious how all that is impacting things or not.

Steven Adam Lisi: I don’t think it’s impacting us that much. I mean, we manufacture in the United States for LungFit, so the vast majority of our costs are in the U.S. We do source some parts from outside the U.S., but it’s not a major impact if those tariffs and some of the big ones are going to stay in place. It’s a low single-digit percentage impact on our cost of goods. So it’s not a major impact on us. And on the reverse side, we haven’t really seen anything about where we’re shipping to in terms of tax on the other end at this point. And as for Israel and Ukraine, I mean honestly, it wasn’t — Israel is great to be in. It’s not a large country but it will impact our ex U.S. sales. We’re very happy to be there. But I don’t think it’s a major driver like a France or a Turkey or Australia, India.

These are much bigger countries where we are. And to be honest, we were very surprised and happy that the distributor that we’re working with in Eastern Europe had Ukraine on their list. So we’re very excited to be able to help the distributor there going to Ukraine, but we didn’t — that we didn’t have any expectations for. So that’s just upside.

Justin Howard Walsh: Great. And maybe just a follow-up on that. I’m curious if you’re seeing more uptake in some of those geographies or where you think some of the markets might be a little bigger. I mean, obviously, you just mentioned a couple of them. But I’m wondering if you’re, I don’t know really, I think you’ll take off in India or somewhere in particular.

Steven Adam Lisi: Yes. I mean, it depends. Like they’re all different in terms of regulatory timing. So India, we have a partner but there’s a regulatory process to go through. So the impact from India on this fiscal year will be minimal. And some of the other countries where like Australia, Thailand, France, Romania, Turkey, these places, the regulatory process is already done or a very short time so we’ll get some more impact from them. But it’s like I said earlier on an earlier question, it’s a little too early because there are tender processes in a lot of these countries so it takes time to get in to some hospitals. So we’re going to wait in the next 3, 4, 5 months to see how those go and how many we get and how quickly we get in.

And every country is different so this is new for us as a company and new for this product, even our international team who has experience with this. This is a new product, right? I mean, no one’s ever seen a noncylinder-based nitric oxide system outside the United States before and certainly not 1 that makes it from ambient air. So this is kind of new for everybody. And we have some distributors are extremely excited, jumped at the opportunity and it was a very quick process to sign them up. And others are a little kind of more skeptical, I think, because they can’t believe what the machine does. So I think we’re just in the early stages and it’s exciting and we’ll — I’ll probably have a better idea maybe on the next call or the call after that of where we’re going to move quickly and which country is going to move fastest.

But right now, it’s just kind of feeling it out, and we’re excited to have this many partners in this many countries open to us at this moment in time.

Operator: Our next question is from Yale Jen with Laidlaw & Company.

I-Eh Jen: Congrats on the guidance as well as the performance. We just got about 3 here. The first 1 is that you suggested you will have more than $1.7 million for the next quarter or current ongoing quarter actually and $12 million to $16 million for the fiscal ’26. So what are — so what’s the confidence you can provide that behind these forecasts or projections? And I have a follow-up.

Steven Adam Lisi: Thanks, Yale. I mean, we’re pretty confident. We wouldn’t have put it out if we weren’t. I think the fact that the June quarter ends in 2 weeks, we’re pretty confident it will be $1.7 million. There could be something that happens in the next 2 weeks to pump it up a bit. We can’t really predict that but we’re highly confident in that number. And as for the fiscal year, we’re pretty confident. I mean, we’ve got a lot in the hopper here especially on the international side. Even in the U.S., there’s movement in some areas that we’re excited to see and maybe happening a little bit sooner than we thought. So I’ll give you an example. We have — we’re very flexible with the customers in how they want to structure their contracts.

It’s very easy with our system to be as flexible as they would like us to be. But one of the things we started offering earlier this year is the razor- razorblade model so the purchase of our system and then the ongoing purchase of the consumables, which is mainly the filter. And we’ve gotten some good feedback over the last month or 2 on that model. So we may actually see some hospitals jumping at the opportunity for that rather than the more traditional nitric oxide model, which is how many hours do you use x amount, this is what your annual cost could be divided by 12 and you get paid that per month. That’s really the main way it’s done, but we’re offering this other way of doing it with the purchase model. And we may see some of that in this fiscal year and that’s exciting.

And that gives us some confidence in our numbers because it wasn’t something we were seeing 6 to 9 months ago at all.

I-Eh Jen: Okay, great. That’s very helpful and comforting. And also in the press release, you mentioned you have about 45 hospitals in the United States now either installed or actually as well as using the LungFit systems. So going towards, let’s say, end of this year, fiscal year or maybe or calendar year of this — end of this year, do you anticipate — what might be the estimate or projection of the number of hospitals that you may have, as well as maybe whether you would also see the volume increase per hospital?

Steven Adam Lisi: I definitely see the volume increasing per hospital. We’ve been seeing that for the past 1.5 years. A lot of our hospitals are going over what their estimate was for the year. That’s a good thing. We do offer a discounted hourly rate if they go over. So certainty of price is important for the customer. So I think that may continue. Hopefully, hospitals can get — work with us and get a better handle on what they’re going to use for the year so there’s certainty in what they’re spending. I don’t want to speculate on the total number of hospitals we’re going to have at the end of the fiscal year. While it’s important, not every hospital is created equal. So some hospitals are small in terms of their volume and some are very large in terms of their volume.

So we could have 1 hospital be worth 10 in some cases. So obviously, 45 is a great number. I certainly see it being significantly more than that number at the end of the fiscal year. But I’m not going to take a guess and try to triangulate that exact number right now, Yale. But thank you.

I-Eh Jen: Okay, great. And maybe just squeezing 1 more question. Actually it’s a follow-up to the earlier 1 that for the PMA application. I know this is difficult to predict the time in possible approval. But just let’s assume or maybe if in the “normal” circumstances, would this process maybe take about 12 months to 16 months or shorter? Just curious what would be the sort of reference point we can at least think about.

Steven Adam Lisi: Yes. So there are statistics that FDA puts out about PMAs, and this is a PMA supplement. So FDA puts statistics out about how long these things take so you can see them online. I’d just caution you to take these averages because not every PMA is created equal. We are just a supplement. We basically make nitric oxide the same way with our second-generation system as our first-generation system. A lot of the things that we do are equivalent. It’s obviously smaller. It obviously has some enhanced features, and it obviously is built to be used for transport in ambulances and helicopters and airplanes. So there are some differences, but from how it operates, it’s really not that much different. So could we be quicker than the average that FDA puts out?

Probably. But again, if you look at FDA’s guidelines, it’s 180 days for a PMA supplement and they normally do not hit that 180 days. And it’s not that they can’t hit their time lines. A lot of times, they have questions and that clock will stop while you’re having discussions with FDA. So that’s something that companies don’t control. FDA does, and we’re going to work with them to get this done as quickly as possible. But I just don’t know what that time line will be at this point. We’ll have a better handle once we start discussions with FDA in the next couple of months.

I-Eh Jen: Great. That’s a lot of great colors on the story. And again, congrats.

Operator: Our next question is from Jason Bednar with Piper Sandler.

Joseph Daniel Downing: This is Joe Downing on for Jason. Congrats on the PMA submission. Just wondering if there’s any difference you can call out in the sales process with the 2.0 device versus the 1.0 device. And then just off of that, can you just remind us how much this LungFit 2.0 expands the market?

Steven Adam Lisi: So Joe, thanks for the questions. I mean, we’re not trying to sell this Gen 2 or market the Gen 2 right now, so we’re not going to comment on how the process is different because we don’t have a process yet. We have to wait for approval on that. But as for how it opens the market, I mean, it vastly expands this market. It opens it up for us as a company to every hospital in the world that wants to use nitric oxide. We can get it anywhere. Our Gen 1 is already in remote locations treating patients, so the Gen 2, it will be even easier to do that. So this is something that will change the way people use nitric oxide in the hospital. I think that it will increase volumes overall and again reach hospitals that don’t use nitric right now. So this is, for us, I think and for the industry, it’s a game changer. It really is.

Joseph Daniel Downing: Great. And then just 1 last 1 on the competitive landscape. Your largest peer put out a new offering a number of months ago. Just wondering if you’re seeing anything worth calling out with contract negotiations with hospitals as a result of that launch.

Steven Adam Lisi: Which one are you talking about?

Joseph Daniel Downing: Mallinckrodt.

Steven Adam Lisi: The Mallinckrodt offering?

Joseph Daniel Downing: Yes.

Steven Adam Lisi: Yes, we haven’t seen a change. I mean, the contracts are usually 1, 3 and 5 years in this market. We haven’t really seen any change in that. So at least my team and I haven’t really seen much change. Yes, they’re out there with their new offering and they’re marketing it, for sure. And I think the last time they spoke, they gave an idea of how many hospitals they were in or something or that they were in hospitals. So you can take a look at what their transcript said. So yes, it’s another competitor. It’s another cylinder-based system out there. That’s the fourth cylinder-based system in the United States.

Operator: At this time, we are showing no further questions in queue. This does conclude our question-and-answer session. I would now like to turn the call back over to Steve Lisi for any closing remarks.

Steven Adam Lisi: Just like to thank everybody for joining us today, and we’ll talk to you in August. Thank you.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.